Syndax Pharmaceuticals Announces Board and Executive Changes
Ticker: SNDX · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: SNDX
TL;DR
Syndax board shakeup and exec comp changes announced.
AI Summary
Syndax Pharmaceuticals, Inc. announced on June 24, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can sometimes precede or accompany significant strategic shifts or financial performance issues.
Key Numbers
- 001-37708 — Commission File Number (Identifier for SEC filings)
- 32-0162505 — IRS Employer Identification No. (Tax identification for the company)
Key Players & Entities
- Syndax Pharmaceuticals, Inc. (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 730 THIRD AVENUE FLOOR 9 (address) — Principal Executive Offices
- NEW YORK, New York (location) — City, State of Principal Executive Offices
- 10017 (zip_code) — Zip Code of Principal Executive Offices
- (781) 419-1400 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and the departure of certain officers, but the specific names and details of these changes are not provided in the excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not included in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 24, 2025.
What is Syndax Pharmaceuticals, Inc.'s principal executive office address?
The principal executive offices are located at 730 THIRD AVENUE FLOOR 9, NEW YORK, New York, 10017.
What is the company's Commission File Number?
The Commission File Number for Syndax Pharmaceuticals, Inc. is 001-37708.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Syndax Pharmaceuticals Inc (SNDX).